Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/22/2008

uction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release and made by our management on the conference call, particularly those anticipating future financial performance, the results of clinical trials, the business prospects for our lead drug candidates Sulonex(TM), Zerenex(TM) and KRX-0401, our growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete cost-effective clinical trials or meet anticipated development timelines for the drug candidates in our pipeline, including Sulonex(TM), Zerenex(TM) and KRX-0401, due to recruitment, clinical trial results, or manufacturing capabilities; our ability to finalize the new drug application for Sulonex before year-end, even if we receive positive results from the Phase 3 study, for various reasons including the completion of necessary non-clinical studies; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This pres
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals Announces Additions to Management Team
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
8. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Once more, ... provide a larger packaged waste water treatment plant to ... Abdullah Economic City (KAEC). Two years ago Bioshaft successfully ... Gate Development, serving two residential towers with an occupancy ... over a quarter million gallons per day and was ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... 28 Today the Swiss,pharmaceutical group Helsinn announced ... Inc. with headquarters in,Bridgewater, New Jersey, for an ... establishment of a US-based R&D and commercial operation ... strategic goals. "We are,thrilled at this very important ...
... Jan. 28 BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) ... host a conference call and webcast on,Wednesday, February 18, at ... year 2008 financial results. , , U.S. ... Dial-in Number: 617.213.8835, Participant Code: 35749059, ...
... Cytopia Ltd (ASX: CYT) has joined with other Progen Pharmaceuticals ... elect a new board, pursue a merger and enable the first ... Progen shareholders include: , , ... so the opportunity of having their shares bought back for $1.10 ...
Cached Biology Technology:Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 2Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 2Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 3Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 4Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 5
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... the January and February issues of the Journal ... and colleagues have extensively characterized a previously unidentified process ... membrane can be reversibly endocytosed. This massive endocytosis ... types with a range of different experimental manipulations, including ...
... has been shown to significantly reduce the symptoms of premenstrual ... Reproductive Health tested the tablets by carrying out ... Filho worked with a team of researchers from the Federal ... "The administration of 1 or 2 grams of essential fatty ...
... , HOUSTON A small slice of RNA inhibits prostate ... prostate cancer stem cells. A research team led by scientists ... today in an advance online publication at Nature Medicine ... microRNA expression pattern in prostate cancer stem cells and also ...
Cached Biology News:MicroRNA suppresses prostate cancer stem cells and metastasis 2
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
Kit for Detection of Mitochondrial Membrane Potential...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MOUSE ANTI HUMAN C-MYC aa171-188...
Biology Products: